<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03885596</url>
  </required_header>
  <id_info>
    <org_study_id>CA-PS-205</org_study_id>
    <nct_id>NCT03885596</nct_id>
  </id_info>
  <brief_title>Open-Label CA-008 (Vocacapsaicin) in Bunionectomy</brief_title>
  <official_title>An Open-Label Study of Intraoperative CA-008 Administration in Subjects Undergoing Bunionectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concentric Analgesics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concentric Analgesics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, open-label study of CA-008 to evaluate post-surgical pain control with CA-008.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, single-center, open-label study evaluating a single dose of CA-008 4.2 mg&#xD;
      administered with different standard-of-care anesthetic regimens during an elective&#xD;
      unilateral transpositional first metatarsal osteotomy for the correction of hallux valgus&#xD;
      deformity (bunionectomy).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Actual">October 22, 2019</completion_date>
  <primary_completion_date type="Actual">July 2, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of Numerical Rating Scale (NRS) Scores (at Rest) Over 72h</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Area Under the Curve of pain intensity scores (using a Numeric Rating Scale of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable) over 72 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Intensity Scores at 24 Hours at Rest Using Numerical Rating Scale (NRS)</measure>
    <time_frame>24 hours</time_frame>
    <description>Numeric Rating Scale (NRS) of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable at 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Intensity Scores at 48 Hours at Rest Using Numerical Rating Scale (NRS)</measure>
    <time_frame>48 hours</time_frame>
    <description>Numeric Rating Scale (NRS) of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable at 48 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Intensity Scores at 72 Hours at Rest Using Numerical Rating Scale (NRS)</measure>
    <time_frame>72 hours</time_frame>
    <description>Numeric Rating Scale (NRS) of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable at 72 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Summary of opioid consumption in oral morphine equivalents</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>CA-008 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block followed by a sciatic (popliteal) nerve block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CA-008 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CA-008 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exparel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>106 mg [8 mL of the 133 mg/10 mL suspension] only&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CA-008</intervention_name>
    <description>Drug: CA-008 4.2 mg reconstituted in saline</description>
    <arm_group_label>CA-008 Cohort 1</arm_group_label>
    <arm_group_label>CA-008 Cohort 2</arm_group_label>
    <arm_group_label>CA-008 Cohort 3</arm_group_label>
    <other_name>Vocacapsaicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>30 mg IV at the onset of anesthesia</description>
    <arm_group_label>CA-008 Cohort 1</arm_group_label>
    <arm_group_label>CA-008 Cohort 2</arm_group_label>
    <arm_group_label>CA-008 Cohort 3</arm_group_label>
    <arm_group_label>Exparel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen IV</intervention_name>
    <description>1 g at the onset of anesthesia</description>
    <arm_group_label>CA-008 Cohort 1</arm_group_label>
    <arm_group_label>CA-008 Cohort 2</arm_group_label>
    <arm_group_label>CA-008 Cohort 3</arm_group_label>
    <arm_group_label>Exparel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery</description>
    <arm_group_label>CA-008 Cohort 1</arm_group_label>
    <arm_group_label>CA-008 Cohort 2</arm_group_label>
    <arm_group_label>CA-008 Cohort 3</arm_group_label>
    <arm_group_label>Exparel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride</intervention_name>
    <description>0.25% 30 mL (75 mg) prior to surgery</description>
    <arm_group_label>CA-008 Cohort 1</arm_group_label>
    <arm_group_label>CA-008 Cohort 2</arm_group_label>
    <arm_group_label>CA-008 Cohort 3</arm_group_label>
    <arm_group_label>Exparel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine HCl</intervention_name>
    <description>1.5% 12 mL at the end of surgery</description>
    <arm_group_label>CA-008 Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>200 mg PO bid each day postoperative</description>
    <arm_group_label>CA-008 Cohort 1</arm_group_label>
    <arm_group_label>CA-008 Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen Oral</intervention_name>
    <description>1 g postoperative</description>
    <arm_group_label>CA-008 Cohort 1</arm_group_label>
    <arm_group_label>CA-008 Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine Hydrochloride</intervention_name>
    <description>2% 15 mL at the end of surgery</description>
    <arm_group_label>CA-008 Cohort 2</arm_group_label>
    <arm_group_label>CA-008 Cohort 3</arm_group_label>
    <arm_group_label>Exparel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <description>Bupivacaine liposome injection suspension</description>
    <arm_group_label>Exparel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult aged 18 - 65 years old&#xD;
&#xD;
          2. American Society of Anesthesiology (ASA) physical Class 1, 2 or 3&#xD;
&#xD;
          3. Planning elective Bunionectomy repair&#xD;
&#xD;
          4. For both males and females: using an acceptable method of birth control&#xD;
&#xD;
          5. If a female: not pregnant or breastfeeding&#xD;
&#xD;
          6. Have a body mass index â‰¤ 36 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have another painful condition, other than bunion-related pain, that may require pain&#xD;
             treatment during the study period&#xD;
&#xD;
          2. Have active skin disease or another abnormality at the anticipated site of surgery&#xD;
             that could interfere with the planned surgery.&#xD;
&#xD;
          3. Have a known allergy to study medications.&#xD;
&#xD;
          4. Have a history of significant medical, neuropsychiatric or other condition, including&#xD;
             a clinically significant abnormal clinical laboratory test values&#xD;
&#xD;
          5. Have positive results on the alcohol test (breath or saliva) or urine drug screen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Wu</last_name>
    <role>Study Director</role>
    <affiliation>Concentric Analgesics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lotus Clinical Research, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <results_first_submitted>August 12, 2021</results_first_submitted>
  <results_first_submitted_qc>September 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 27, 2021</results_first_posted>
  <disposition_first_submitted>September 12, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>September 29, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 27, 2021</disposition_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT03885596/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT03885596/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CA-008 Cohort 1</title>
          <description>CA-008 4.2 mg&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block followed by a sciatic (popliteal) nerve block.&#xD;
CA-008: Drug: CA-008 4.2 mg&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine HCl: 1.5% 12 mL at the end of surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative</description>
        </group>
        <group group_id="P2">
          <title>CA-008 Cohort 2</title>
          <description>CA-008 4.2 mg&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
        </group>
        <group group_id="P3">
          <title>CA-008 Cohort 3</title>
          <description>CA-008 4.2 mg&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
        </group>
        <group group_id="P4">
          <title>Exparel</title>
          <description>106 mg [8 mL of the 133 mg/10 mL suspension] only&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery&#xD;
Exparel: Bupivacaine liposome injection suspension</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CA-008 (Vocacapsaicin) Cohort 1</title>
          <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block followed by a sciatic (popliteal) nerve block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine HCl: 1.5% 12 mL at the end of surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative</description>
        </group>
        <group group_id="B2">
          <title>CA-008 (Vocacapsaicin) Cohort 2</title>
          <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
        </group>
        <group group_id="B3">
          <title>CA-008 (Vocacapsaicin) Cohort 3</title>
          <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
        </group>
        <group group_id="B4">
          <title>Exparel</title>
          <description>106 mg [8 mL of the 133 mg/10 mL suspension] only&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery&#xD;
Exparel: Bupivacaine liposome injection suspension</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.1" spread="9.96"/>
                    <measurement group_id="B2" value="43.1" spread="9.20"/>
                    <measurement group_id="B3" value="35.2" spread="12.71"/>
                    <measurement group_id="B4" value="52.8" spread="6.72"/>
                    <measurement group_id="B5" value="45.05" spread="9.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) of Numerical Rating Scale (NRS) Scores (at Rest) Over 72h</title>
        <description>Area Under the Curve of pain intensity scores (using a Numeric Rating Scale of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable) over 72 hours</description>
        <time_frame>0-72 hours</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>CA-008 Cohort 1</title>
            <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block followed by a sciatic (popliteal) nerve block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine HCl: 1.5% 12 mL at the end of surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative</description>
          </group>
          <group group_id="O2">
            <title>CA-008 Cohort 2</title>
            <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
          </group>
          <group group_id="O3">
            <title>CA-008 Cohort 3</title>
            <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
          </group>
          <group group_id="O4">
            <title>Exparel</title>
            <description>106 mg [8 mL of the 133 mg/10 mL suspension] only&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery&#xD;
Exparel: Bupivacaine liposome injection suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Numerical Rating Scale (NRS) Scores (at Rest) Over 72h</title>
          <description>Area Under the Curve of pain intensity scores (using a Numeric Rating Scale of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable) over 72 hours</description>
          <population>Safety population</population>
          <units>score on a scale*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.30" spread="95.476"/>
                    <measurement group_id="O2" value="66.24" spread="54.365"/>
                    <measurement group_id="O3" value="203.76" spread="103.718"/>
                    <measurement group_id="O4" value="306.58" spread="92.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Consumption</title>
        <description>Summary of opioid consumption in oral morphine equivalents</description>
        <time_frame>0-72 hours</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>CA-008 (Vocacapsaicin) Cohort 1</title>
            <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block followed by a sciatic (popliteal) nerve block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine HCl: 1.5% 12 mL at the end of surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative</description>
          </group>
          <group group_id="O2">
            <title>CA-008 (Vocacapsaicin) Cohort 2</title>
            <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
          </group>
          <group group_id="O3">
            <title>CA-008 (Vocacapsaicin) Cohort 3</title>
            <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
          </group>
          <group group_id="O4">
            <title>Exparel</title>
            <description>106 mg [8 mL of the 133 mg/10 mL suspension] only&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery&#xD;
Exparel: Bupivacaine liposome injection suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption</title>
          <description>Summary of opioid consumption in oral morphine equivalents</description>
          <population>Safety population</population>
          <units>mg morphine equivalents</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.83" spread="27.33"/>
                    <measurement group_id="O2" value="3.33" spread="6.61"/>
                    <measurement group_id="O3" value="38.33" spread="26.90"/>
                    <measurement group_id="O4" value="80.83" spread="66.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity Scores at 24 Hours at Rest Using Numerical Rating Scale (NRS)</title>
        <description>Numeric Rating Scale (NRS) of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable at 24 hours</description>
        <time_frame>24 hours</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>CA-008 Cohort 1</title>
            <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block followed by a sciatic (popliteal) nerve block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine HCl: 1.5% 12 mL at the end of surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative</description>
          </group>
          <group group_id="O2">
            <title>CA-008 Cohort 2</title>
            <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
          </group>
          <group group_id="O3">
            <title>CA-008 Cohort 3</title>
            <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
          </group>
          <group group_id="O4">
            <title>Exparel</title>
            <description>106 mg [8 mL of the 133 mg/10 mL suspension] only&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery&#xD;
Exparel: Bupivacaine liposome injection suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Scores at 24 Hours at Rest Using Numerical Rating Scale (NRS)</title>
          <description>Numeric Rating Scale (NRS) of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable at 24 hours</description>
          <population>Safety population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.88"/>
                    <measurement group_id="O2" value="1.7" spread="1.66"/>
                    <measurement group_id="O3" value="5.1" spread="1.45"/>
                    <measurement group_id="O4" value="6.0" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity Scores at 48 Hours at Rest Using Numerical Rating Scale (NRS)</title>
        <description>Numeric Rating Scale (NRS) of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable at 48 hours</description>
        <time_frame>48 hours</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>CA-008 Cohort 1</title>
            <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block followed by a sciatic (popliteal) nerve block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine HCl: 1.5% 12 mL at the end of surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative</description>
          </group>
          <group group_id="O2">
            <title>CA-008 Cohort 2</title>
            <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
          </group>
          <group group_id="O3">
            <title>CA-008 Cohort 3</title>
            <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
          </group>
          <group group_id="O4">
            <title>Exparel</title>
            <description>106 mg [8 mL of the 133 mg/10 mL suspension] only&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery&#xD;
Exparel: Bupivacaine liposome injection suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Scores at 48 Hours at Rest Using Numerical Rating Scale (NRS)</title>
          <description>Numeric Rating Scale (NRS) of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable at 48 hours</description>
          <population>Safety population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.12"/>
                    <measurement group_id="O2" value="0.6" spread="0.73"/>
                    <measurement group_id="O3" value="2.7" spread="2.45"/>
                    <measurement group_id="O4" value="4.8" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity Scores at 72 Hours at Rest Using Numerical Rating Scale (NRS)</title>
        <description>Numeric Rating Scale (NRS) of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable at 72 hours</description>
        <time_frame>72 hours</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>CA-008 Cohort 1</title>
            <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block followed by a sciatic (popliteal) nerve block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine HCl: 1.5% 12 mL at the end of surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative</description>
          </group>
          <group group_id="O2">
            <title>CA-008 Cohort 2</title>
            <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
          </group>
          <group group_id="O3">
            <title>CA-008 Cohort 3</title>
            <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
          </group>
          <group group_id="O4">
            <title>Exparel</title>
            <description>106 mg [8 mL of the 133 mg/10 mL suspension] only&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery&#xD;
Exparel: Bupivacaine liposome injection suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Scores at 72 Hours at Rest Using Numerical Rating Scale (NRS)</title>
          <description>Numeric Rating Scale (NRS) of pain intensity from 0-10 where 0 is no pain and 10 is the worst pain imaginable at 72 hours</description>
          <population>Safety population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="2.28"/>
                    <measurement group_id="O2" value="0.3" spread="0.71"/>
                    <measurement group_id="O3" value="2.0" spread="2.12"/>
                    <measurement group_id="O4" value="4.6" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 76 days: Screening period from 45 days prior to surgery (D-45) to D29Â±2 Study Completion Visit. Unscheduled visits or visits after D29 might be necessary to assess ongoing safety issues or to follow an event to resolution or to establishment of a new baseline.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CA-008 Cohort 1</title>
          <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block followed by a sciatic (popliteal) nerve block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine HCl: 1.5% 12 mL at the end of surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative</description>
        </group>
        <group group_id="E2">
          <title>CA-008 Cohort 2</title>
          <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Celecoxib: 200 mg PO bid each day postoperative&#xD;
Acetaminophen Oral: 1 g postoperative&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
        </group>
        <group group_id="E3">
          <title>CA-008 Cohort 3</title>
          <description>CA-008 4.2 mg reconstituted in saline&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
CA-008: Drug: CA-008 4.2 mg reconstituted in saline&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery</description>
        </group>
        <group group_id="E4">
          <title>Exparel</title>
          <description>106 mg [8 mL of the 133 mg/10 mL suspension] only&#xD;
All subjects received monitored anesthesia care (MAC) and a Mayo block.&#xD;
Ketorolac: 30 mg IV at the onset of anesthesia&#xD;
Acetaminophen IV: 1 g at the onset of anesthesia&#xD;
Fentanyl: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery&#xD;
Bupivacaine Hydrochloride: 0.25% 30 mL (75 mg) prior to surgery&#xD;
Lidocaine Hydrochloride: 2% 15 mL at the end of surgery&#xD;
Exparel: Bupivacaine liposome injection suspension</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Operations</name_or_title>
      <organization>Concentric Analgesics</organization>
      <phone>14154847921</phone>
      <email>nancy@concentricanalgesics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

